Key Points
- Lantern Pharma director D. Jeffrey Keyser bought 48,544 shares on May 12 at an average price of $2.06 each, a transaction worth about $100,000.64. His direct ownership rose to 94,303 shares, reflecting a 106.09% increase.
- The stock recently opened at $3.13, giving Lantern Pharma a market cap of about $35.4 million. Its shares have traded between $1.11 and $5.74 over the past year.
- Wall Street sentiment remains weak, with the company carrying an average Sell rating from analysts. Meanwhile, Lantern Pharma reported a narrower-than-expected quarterly loss, posting EPS of ($0.36) versus consensus estimates of ($0.46).
Lantern Pharma Inc. (NASDAQ:LTRN - Get Free Report) Director D Jeffrey Keyser acquired 48,544 shares of the firm's stock in a transaction that occurred on Tuesday, May 12th. The stock was purchased at an average cost of $2.06 per share, for a total transaction of $100,000.64. Following the completion of the purchase, the director directly owned 94,303 shares of the company's stock, valued at $194,264.18. The trade was a 106.09% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Lantern Pharma Price Performance
Shares of NASDAQ:LTRN opened at $3.13 on Friday. The company's 50 day simple moving average is $2.22 and its 200 day simple moving average is $2.92. The stock has a market capitalization of $35.40 million, a price-to-earnings ratio of -1.99 and a beta of 2.10. Lantern Pharma Inc. has a 1 year low of $1.11 and a 1 year high of $5.74.
Lantern Pharma (NASDAQ:LTRN - Get Free Report) last announced its quarterly earnings data on Monday, March 30th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.46) by $0.10.
Institutional Trading of Lantern Pharma
Institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its stake in shares of Lantern Pharma by 5.6% in the third quarter. Vanguard Group Inc. now owns 384,041 shares of the company's stock worth $1,671,000 after purchasing an additional 20,321 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of Lantern Pharma by 10.3% in the fourth quarter. Renaissance Technologies LLC now owns 110,400 shares of the company's stock worth $335,000 after purchasing an additional 10,300 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Lantern Pharma by 5.1% in the fourth quarter. Geode Capital Management LLC now owns 96,742 shares of the company's stock worth $293,000 after purchasing an additional 4,661 shares during the last quarter. Susquehanna International Group LLP bought a new stake in shares of Lantern Pharma in the third quarter worth $170,000. Finally, Two Sigma Investments LP bought a new stake in shares of Lantern Pharma in the third quarter worth $70,000. Institutional investors own 28.62% of the company's stock.
Wall Street Analyst Weigh In
A number of research firms have weighed in on LTRN. Weiss Ratings raised shares of Lantern Pharma from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday, May 7th. Wall Street Zen raised shares of Lantern Pharma to a "sell" rating in a research note on Saturday, May 9th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of "Sell".
Read Our Latest Stock Report on LTRN
About Lantern Pharma
(
Get Free Report)
Lantern Pharma, Inc is a clinical-stage oncology company leveraging artificial intelligence (AI) and machine learning to accelerate the discovery and development of targeted cancer therapies. Headquartered in Dallas, Texas, Lantern Pharma's proprietary RADR® platform integrates large-scale genomic, transcriptomic and chemical data to identify novel drug candidates and predict patient populations most likely to benefit from treatment.
The company's pipeline focuses on molecules designed to address cancers with high unmet medical need.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
